ABSTRACT IFN-g-inducible protein 10 (CXCL10), a chemokine that is abundantly secreted in response to inflammatory stimuli, has been implicated in the pathogenesis of multiple inflammatory diseases, such as inflammatory bowel disease. Whereas CXCL10 is traditionally recognized for recruiting pathogenic T cells to inflamed sites, its nonchemotactic role during inflammation remains poorly defined. In this report, we identified a novel function of CXCL10 in the regulation of the inflammatory potential of human monocytes to produce cytokines. We found that CXCL10 was necessary and sufficient for IFN-g-primed human monocytes to induce a robust production of proinflammatory cytokines, such as IL-12 and IL-23. CXCL10-induced monocyte production of these cytokines depended on CXCR3 receptor engagement as well as on the Ik B kinase and p38 MAPK signaling pathways. By using an innate-mediated murine colitis model, we demonstrated that anti-CXCL10 Ab treatment robustly suppressed the local production of myeloid-derived inflammatory cytokines and intestinal tissue damage. Together, our data unravel a previously unappreciated role of CXCL10 in the amplification of myeloid cellmediated inflammatory responses. Targeting CXCL10 is therefore an attractive approach to treating inflammatory diseases that are driven by innate and adaptive immunity.
Introduction
Inflammatory bowel diseases, including both ulcerative colitis and Crohn's disease results, at least in part, from the dysregulation of both the innate and adaptive arms of the immune system [1, 2] . Innate immune dysregulation involves both myeloid cells and ILCs, whereas adaptive immune abnormalities center on T cells, particularly CD4
+ helper T cells. Recent advancements in the understanding of basic biology of myeloid cells and ILCs, particularly in the intestine, have prompted a research focus on both innate cell types in the field of IBD [3] .
Monocytes (and macrophages), a subtype of myeloid cells, are some of the most abundant leukocytes in the intestinal mucosa where they are essential for maintaining homeostasis in the normal gut [4, 5] . The dysregulation of monocytes is implicated in IBD pathogenesis. One key feature of intestinal monocytes/ macrophages-in contrast to other tissue-resident macrophages-is that they are continually renewed from circulating monocytes [6] . The functional importance of monocytes in IBD pathogenesis is highlighted by the abundance of monocyte/ macrophage-derived cytokines that are produced at the intestinal mucosa, including TNF-a, IL-12p40, and IL-23p19, and by the effectiveness of therapies that target these cytokines [5] . Although much progress has been made in understanding the phenotype and function of these myeloid cells, the molecular mechanisms by which they are activated remain poorly characterized.
CXCL10 (IFN-g-inducible protein 10), a CXC chemokine, is secreted by immune cells (T, B, NK, and myeloid) and nonimmune cells (epithelial, endothelial, and fibroblast) in response to such inflammatory stimuli as IFN-g, TNF-a, and IL-1b [7, 8] . It is constitutively found in blood and normal tissues (e.g., the colon), and its expression is significantly increased in circulation under systemic inflammation and in diseased tissues. Of note, CXCL10 is one of the most abundant proteins that are detected in the circulation of patients with several autoimmune diseases, including IBD, and it is also abundantly present in inflamed tissues [9] . CXCL10 acts on its target cells via both CXCR3 and non-CXCR3 receptors on the surfaces of various cell types. For immune cells (T, NK, and ILC) and some nonimmune cells (oligodendrocyte precursor and neurons) [10, 11] , it binds to and activates CXCR3, which leads to the activation of a variety of downstream pathways; for endothelial cells, it functions by binding to glycosaminoglycan [12] ; and for epithelial cells [13, 14] , it seems to use an unidentified receptor that is neither CXCR3, nor glycosaminoglycan [15] , although CXCR3 studies on endothelial and epithelial cells are underway in limited contexts.
It has long been considered that CXCL10 primarily functions to recruit immune cells and has been classically described as a T cell chemoattractant, with more recent understanding in NK and macrophage cell recruitment to inflamed tissues in inflammatory diseases [16] . However, growing evidence has shown that CXCL10 has roles beyond immune cell recruitment, including nonchemotactic functions of both immune and nonimmune cells types. These nonchemotactic functions include promoting the differentiation of activated CD4 + T cells into Th1
and Th17 [17, 18] and the differentiation of activated B cells into plasma cells [19] , as well as promoting the apoptosis of endothelial cells [12] , islet cells [20] , oligodendricyte progenitors [10] , and neurons [11] . In line with these nonchemotactic cellular functions, CXCL10 induces the noncanonical signaling pathways of CXCR3, which are independent of GaI, and dependent on STAT1/4/5 [17] , p38 MAPK/PI3K [21] , and ERK1/2 [11] .
Here, we report a critical role for CXCL10 in mediating the production of proinflammatory cytokines, such as IL-12p70, in activated monocytes, a previously unappreciated nonchemotactic function of CXCL10. Among the monocyte-derived chemokines that are produced in response to IFN-g priming, CXCL10 is produced earlier than its related chemokines, CXCL9 (MIG) and CXCL11 (iTAC), and exerts the most potent stimulatory effect on proinflammatory cytokine (i.e., IL-12) production from activated monocytes. Furthermore, CXCL10, but not CXCL9 or CXCL11, sufficed to potentiate the ability of IFN-g-primed monocytes to produce IL-12. In keeping with these in vitro findings, the inhibition of CXCL10 in vivo suppressed the production of IL-12 and other proinflammatory cytokines that are produced by myeloid-derived cells in CD40-mediated colitis in SCID mice, an innate immune-mediated IBD model [22, 23] . Furthermore, the blockade of CXCL10-mediated cytokine production resulted in the amelioration of inflammatory responses and tissue damage in the intestines. We discuss the implications of these findings in the pathogenesis and treatment of inflammatory diseases.
MATERIALS AND METHODS

Isolation of human monocytes
Peripheral blood was collected from volunteer donors who were recruited under approval from the Bristol-Myers Squibb Research Ethics Board. All donors were healthy and exhibited no sign of active infectious or atopic disease. Blood cells were layered over a Ficoll gradient (Lymphoprep; Stemcell Technologies, Vancouver, BC, Canada). After centrifugation (1800 rpm, 20 min), PBMCs were isolated, washed, and resuspended in PBS (pH 7.2) that was supplemented with 2% FBS and 1 mM EDTA. PBMCs were incubated with the Human Monocytes Enrichment Cocktail without CD16 depletion (Stemcell Technologies) at 2-8°C for 10 min, according to manufacturer instructions. After washing, the negatively selected enriched cells were used for assays. The purity of enriched monocytes reached typically 90-95% by flow cytometric assessment.
Monocyte cultures and macrophage differentiation
For monocyte stimulation, isolated monocytes (0.5 3 10 5 cells) were cultured in 96-well flat-bottom culture plates in 0.1 ml RPMI 1640 culture medium. Macrophages were differentiated from isolated monocytes by culturing them for 6 d in the presence of M-CSF (50 ng/ml; R&D Systems, Minneapolis, MN, USA) in RPMI 1640 media with replacement at day 3. Cells were incubated in triplicate at 37°C, 5% CO 2 for 24 h with IFN-g (100 ng/ml; R&D Systems) in the presence or absence of anti-CXCL10 mAb (10 mg/ml) and control human IgG. Cultures were then carried out with medium or with LPS (1 mg/ml; Sigma-Aldrich, St. Louis, MO, USA) or other indicated TLR ligands (1 mg/ml per each; Sigma-Aldrich) for another 24 h. After 48 h, supernatants were collected for the measurement of cytokines and chemokines. In a subset of experiments, monocytes were cultured for 24 h with IFN-g (2 mg/ml), with a gentle wash 3 times with RPMI 1640 culture medium before the addition of human CXCL10/IFN-g-inducible protein 10 (4 mg/ml) in the presence of anti-CXCL10 mAb (100 mg/ml, see below), anti-CXCL9/CXCL11 (100 mg/ml, polyclonal goat IgG; R&D Systems), or control IgG1. After 48 h of culture, supernatants were collected and measured for cytokines and chemokines.
To inhibit intracellular signaling pathways, IFN-g-primed monocytes were washed and treated with small-molecule inhibitors before CXCL10 stimulation. Inhibitors used include pertussis toxin and U0126 (Sigma-Aldrich), p38 MAPK (TAK 715; Tocris Bioscience, Bristol, United Kingdom), IKK (BMS 345541; Tocris Bioscience), and BTK (GL47; EMD Millipore, Billerica, MA, USA) at 1-10 nM ranges.
Measurements of CXCL10 in the serum and colon tissues of patients with IBD
Both the human colon and serum samples of patients with IBD-ulcerative colitis and Crohn's disease, respectively-were obtained commercially (Analytical Biologic Services, Wilmington, DE, USA). Healthy volunteer samples are identified as individuals without a history of IBD or acute or systemic intestinal infection that required antibiotics. Human colon samples were analyzed by using the immunoprecipitation LC-MS/MS method for the quantitative determination of CXCL-10. AB Sciex Triple Quad 6500 system (ABI/MDS Sciex, Concord, ON, Canada) that was equipped with a TurboIonSpray source was used for surrogate peptide detection. The peptide, VEIIATMK, was selected as the surrogate peptide. Two SRM transitions, 452.8 . 229.1 and 452.8 . 676. 4 , that corresponded to the two product ions were monitored for the surrogate peptide. A Shimadzu Nexera LC-30AD UHPLC system (Shimadzu, Kyoto, Japan) was coupled to the mass spectrometer for LC separation. Colon samples were homogenized and the supernatant was collected by centrifugation. Immunoprecipitation was carried out by using magnetic beads that were conjugated with anti-human CXCL10 Ab. CXCL10 was captured and unbound matrix components were washed away. Subsequently, the samples were digested by trypsin, then injected for LC-MS/MS analysis. The standard curve range is from 1 to 1000 pM. Serum samples were analyzed by using the LC-MS/MS method for the quantitative determination of CXCL10, as described previously [9] . immunized mice were then fused (1:1) with mouse 363.Ag8.653 myeloma cells (CRL-1581; American Type Culture Collection, Manassas, VA, USA) by electrofusion (Hybrimmune, ECM 2001; Harvard Apparatus, Holliston, MA, USA). The resulting hybridomas were plated out in flat-bottom 96-well plates (200 ml/well) and incubated for 7 d in HAT selection medium [DMEM that was supplemented with 10% FBS, 2 mM glutamine, 5% BM-Condimed H1 Hybridoma Cloning Supplement (Roche Diagnostics, Atlanta, GA, USA), and 13 HAT] and an additional 7 d in 13 sodium hypoxanthine and thymidine selection medium (same medium supplemented with 13 sodium hypoxanthine and thymidine instead of HAT). Hybridoma supernatants were then screened by ELISA for antigen specificity. Antigen-specific clones were subcloned by limiting the dilution to achieve stability and monoclonality. Clones of interest were expanded and Abs were purified from culture supernatant over protein A column. Hybridoma clones were preserved by freezing in 10% DMSO freezing media (Sigma-Aldrich). The specificity of the purified anti-mouse CXCL10 Ab (clone 18G2) was confirmed in cell-based assays. The mouse CXCR3 + 300.19 mouse lymphoma cell line was treated with CXCL10 in the presence of 18G2 and control IgG2a, and CXCL10-indcued calcium influx was measured. 18G2 was used in vivo for colitis studies. An antihuman CXCL10 Ab with high affinity was generated at Bristol-Myers Squibb after in vitro affinity maturation of the anti-human CXCL10 Ab (BMS-936557) [9] with proprietary technology and did not cross-react with human CXCL9 and CXCL11.
ELISA
Culture supernatants and serum samples were taken and used for ELISA to quantify cytokine/chemokine expression according to manufacturer guidelines. Murine IL-12, IL-23, TNF-a, and CXCL9/10/11 were measured by using a Luminex Bead-based Multiplex Assay (R&D Systems), and, in some cases, Ready-Set-Go! ELISA kits (eBioscience, San Diego, CA, USA 
Animal studies
Female C57BL/6 mice (age 8 wk, weight 18-22 g; The Jackson Laboratory, Bar Harbor, ME, USA) used for this study were group-housed under controlled temperature (25°C) and photoperiod (12-h light/dark cycle) conditions and given unrestricted access to standard diet and tap water (or specified drinking solution). SCID mice were purchased from Taconic (C.B-Igh-1 b /lcr Tac-Prkdc scid ; Hudson, NY, USA), bred, and maintained under specific pathogenfree conditions. All procedures that involved animals were reviewed and approved by the Bristol-Myers Squibb Institutional Animal Care and Use Committee.
Anti-CD40-induced colitis
Seven-to twelve-week-old sex-matched female and male SCID mice were i.p. injected with 200 mg anti-CD40 (clone FGK4.5; Bio X Cell, West Lebanon, NH, USA) on day 0. Colonic inflammation was assessed 6-8 d after anti-CD40 Ab treatment. At least 6 mice were included in each group. Colon and small intestine were removed, cleaned, and processed as described previously [22] . To neutralize CXCL10 or TNF-a, mice were i.p. injected on day 0 (2 h before anti-CD40 injection) with 25 mg/kg anti-CXCL10 (clone 18G2) and control mouse IgG2a or PBS. PBS and rat IgG produced identical results and were interchangeably used.
Histology
Colonic strips were fixed in 10% phosphate-buffered formalin overnight, transferred to 70% ethanol, and processed routinely with paraffin embedding. Five-micrometer sections were stained with H&E. Images were obtained by using a Zeiss Axioskop 2 plus microscope (Carl Zeiss, Jena, Germany) that was equipped with an AxioCam MRc5 CCD camera (Carl Zeiss). H&E-stained colonic sections were coded for blind microscopic assessment of inflammation. Histologic scoring was based on 3 parameters. The severity of inflammation was scored as follows: 0 = rare inflammatory cells in the lamina propria; 1 = increased numbers of granulocytes in the lamina propria; 2 = confluence of inflammatory cells extending into the submucosa; and 3 = transmural extension of the inflammatory infiltrate. Crypt damage was scored as follows: 0 = intact crypts; 1 = loss of the basal one third; 2 = loss of the basal two thirds; 3 = entire crypt loss; 4 = change of epithelial surface with erosion; and 5 = confluent erosion. Ulceration was scored as follows: 0 = absence of ulcer; 1 = 1 or 2 foci of ulcerations; 2 = 3 or 4 foci of ulcerations; and 3 = confluent or extensive ulceration. Values were added to give a maximal histologic score of 11.
Leukocyte isolation and flow cytometry
For flow cytometry, murine colon LPLs were isolated as described previously [22] and the surface was stained with fluorochrome-labeled anti-CD45, antiLy6C (AL-21), and anti-Ly6G (18A) Abs purchased from BioLegend (San Diego, CA, USA). For intracellular cytokine staining, single-cell suspensions from lamina propria were incubated directly in RPMI 1640 media that contained 10% FCS and Golgi plug for 4-5 h or restimulated in 10% FCS RPMI 1640 with PMA (50 ng/ml) and ionomycin (1 mg/ml) in the presence of the Golgi plug. Cell were then permeabilized and fixed by using the FOXP3 staining buffer set according to manufacturer instructions (eBioscience) and intracellularly stained with anti-TNF-a Ab. Human CXCR3 expression was detected by FITC-anti-human CD183 (G025H7; BioLegend). 
Mouse colon organ culture
Colons from treated mice were opened and washed with sterile PBS, cut longitudinally, and rinsed briefly in HBSS (5% FBS and 1% penicillin/ streptomycin) [24] . The mucosa was gently removed by using a cell scraper (BD Falcon, San Jose, CA, USA), followed by washing in HBSS. By using a 4-mm dermal biopsy punch (Integra Miltex, York, PA, USA), colons were cut into 4-3 4-mm pieces and colon explants were cultured in 24-well plates with 0.5 ml RPMI 1640 media (10% FBS and 100 mg/ml gentamicin) at 37°C with 5% CO 2 overnight. At the end of the experiment, supernatants were collected and subjected to an assay for cytokine detection.
Statistical analysis
Statistical analysis was performed by using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Data are presented as average values 6 SD from experiments performed in triplicate (n = 3), with the exception of in vivo experiments (n = 4-8/genotype per experiment). All experiments were repeated as at least 2-3 independent experiments. Samples were analyzed by using Student's t test (2 tailed). A P value of ,0.05 was considered to be significant.
RESULTS
CXCL10 plays a critical role in the production of proinflammatory cytokines by human monocytes
To investigate the role of CXCL10 in the regulation of myeloidderived cells (i.e., monocytes and macrophages), we first explored the effect of CXCL10 on the cytokine production of monocytes that were prepared from PBMCs of normal healthy donors in response to external stimuli, such as microbial products. Freshly isolated human monocytes were pretreated with IFN-g, a potent trigger for CXCL10 [25] , before engagement with TLR ligands, such as LPS. As has been described previously [26] , LPS stimulation of IFN-g-pretreated (i.e., primed) monocytes resulted in the robust production of an array of proinflammatory cytokines, including IL-12, IL-23, TNF-a, and IL-6 ( Fig. 1A and data not shown). Of note, single treatment of the monocytes with either IFN-g (up to 500 ng/ml) or LPS (1 mg/ml) was not sufficient to trigger the production of proinflammatory cytokines, such as IL-12 and IL-23 ( Fig. 1A) . To assess the impact of CXCL10 on the LPSinduced proinflammatory cytokine production by human monocytes, we next analyzed CXCL10 accumulation over time in culture supernatants after IFN-g treatment before LPS stimulation. As expected, CXCL10 proteins were readily detectable as early as 3 h post-IFN-g stimulation and continued to increase, peaking at 24 h (Fig. 1B ). Longer incubation with or without LPS did not result in an additional increase in CXCL10 accumulation (Fig. 1B) . In contrast, we observed minimal, if any, CXCL10 from monocytes after LPS stimulation (,50 pg/ml, n . 50 donors). To determine whether CXCL10 is required for cytokine induction by IFN-gprimed monocytes in response to LPS, CXCL10 signaling was blocked by the inclusion of a newly generated anti-CXCL10 Ab.
Anti-CXCL10 Ab treatment effectively neutralized soluble CXCL10 proteins that were secreted from IFN-g-primed monocytes when measured at 24 h (data not shown). Unexpectedly, the inclusion of neutralizing anti-CXCL10 Ab in parallel with IFN-g stimulation of monocytes (i.e., 0 h) nearly completely abrogated the production of proinflammatory cytokines of LPS-stimulated monocytes, such as IL-12, IL-23, TNF-a, and IL-6 ( Fig. 1C and data not shown) when examined at 48 h. As shown in Fig. 1A , we did not observe any detectable amount of IL-12 or IL-23 with LPS alone. To determine whether continuous CXCL10 signaling is required to promote cytokine (i.e., IL-12) production in response to LPS, anti-CXCL10 Ab was added to the cultures in parallel with LPS triggering (i.e., at 24 h culture). Again, the delayed blockade of CXCL10 signaling dramatically inhibited the production of IL-12 when measured at 48 h (Fig. 1D) , which suggests that CXCL10 induced by IFN-g priming acts in an autocrine fashion on monocytes during TLRtriggered cytokine production. The inhibition of monocytederived proinflammatory cytokine production by anti-CXCL10 mAb treatment was not a result of its effect on cell viability or cellular proliferation because we observed similar numbers of live cells when recovered at 48 h compared with controls. Lastly, when monocyte-derived macrophages were examined for their sensitivity to CXCL10 after IFN-g/LPS stimulation, IL-12 production was again under the level of detection with CXCL10 blockade (Fig. 1E) . Taken together, these data suggest that CXCL10 plays a previously unrecognized critical role in potentiating the production of proinflammatory cytokines by human monocytes/macrophages.
CXCL9 and CXCL11 are largely dispensable for cytokine production by IFN-g-primed human monocytes
Monocytes, upon IFN-g stimulation, produce CXCL9 (Mig) and CXCL11 (iTac) in addition to CXCL10, all of which are well-described ligands for CXCR3 [25] . Our data described in Fig. 1 prompted us to investigate whether CXCL9 and/or CXCL11 also played a nonchemotactic role in the regulation of cytokine production by IFN-g-primed, LPS-stimulated monocytes in a manner similar to CXCL10. We first analyzed CXCL9/11 proteins that had accumulated in the supernatants of IFN-g-primed human monocytes. CXCL9 production was delayed and was detectable at amounts that were significantly lower at 24 h compared with CXCL10; however, we did observe significantly increased CXCL9 production when measured later at 48 h ( Fig. 2A) . In contrast, we failed to detect any measurable amount of CXCL11 proteins even after a longer incubation (Fig. 2A) . To assess the role of CXCL9 and CXCL11 in the modulation of the ability of monocytes to produce proinflammatory cytokines, neutralizing Abs against CXCL9 or CXCL11, respectively, were incubated along with IFN-g treatment of monocytes (i.e., 0 h). Blockade of CXCL9 resulted in a partial but significant inhibition of IL-12 production (;60-70%) when measured at 48 h of incubation (Fig. 2B) . The incomplete inhibition that was observed after anti-CXCL9 Ab treatment did not stem from the incomplete neutralization of CXCL9 proteins in the cultures as we did not detect unbound free CXCL9 when examined with non-cross-reacting anti-CXCL9 Ab (data not shown). However, this finding does not rule out the potential contribution of CXCL9 to priming monocytes (e.g., conditioning/sensitizing) at the earlier time points and subsequently enhancing the effect of CXCL10. Conversely, neutralizing CXCL11 did not demonstrate any measurable effect on the production of IL-12 by activated monocytes (Fig. 2B) . The latter is in line with its minimal production by monocytes after IFN-g priming ( Fig. 2A) . Taken together, our data suggest that CXCL10 differs from CXCL9 or CXCL11 in its capacity to mediate the production of proinflammatory cytokines, including IL-12 from activated monocytes.
CXCL10-dependent promotion of IL-12 production by human monocytes is dependent on CXCR3 receptor engagement and IKK/p38 MAPK signaling pathways
The potency of the impact of CXCL10 on cytokine production by human monocytes is attributable simply to its abundance at the early stage of monocyte activation, which results in a greater receptor engagement and, thus, stronger signaling relative to that of CXCL9 and CXCL11. Alternatively, CXCL10 delivers a signal that is distinct from CXCL9/11 to monocytes in the promotion of the proinflammatory cytokine production. Lastly, the early availability of CXCL10 with sufficient quantity induces the monocytes to respond to CXCL10 over CXCL9/11. To explore these possibilities, we next evaluated whether the provision of each of these chemokines is sufficient for activated monocytes to induce IL-12 production in the absence of TLR engagement. To this end, we treated human monocytes with IFN-g for 24 h, followed by extensive washes before adding an exogenous chemokine, which resulted in the removal of supernatants that contained residual IFN-g added and accumulated endogenous chemokines, including CXCL9 and CXCL10. This allows us to assess whether the freshly added exogenous chemokine (i.e., CXCL10) is sufficient to trigger the primed monocytes to release IL-12. The monocyte response to supplemented CXCL10 was monitored by measuring IL-12 production at 24 h post-treatment (i.e., 48 h). As noted earlier (Fig. 1A) , IFN-g treatment alone, even with escalating doses and prolonged exposures, was not sufficient to trigger IL-12 production (Fig. 3A and data not shown). Similar to responses to endogenous chemokines, IL-12 production was detected from stimulation with CXCL10, but not CXCL9 or CXCL11, when examined over the range of chemokine doses (Fig. 3A) . Furthermore, IL-12 production was specific in response to CXCL10 treatment as the addition of anti-CXCL10 Ab, but not anti-CXCL9 Ab, in cultures substantially prevented monocytes from secreting IL-12 (Fig. 3B) . Taken together, our data demonstrate that CXCL10 was sufficient to deliver a stimulatory signal to primed monocytes to produce proinflammatory cytokines, whereas CXCL9 and CXCL10 failed to trigger monocyte activation in the absence of TLR engagement. The dependence of CXCL10 and, to a lesser extent, CXCL9 on IL-12 production by monocytes prompted us to investigate whether CXCR3-the receptor for both-is required for signaling. The relevance of CXCR3-dependent signaling in IL-12 production was first explored by treating IFN-g-primed monocytes with anti-CXCR3 Ab before the addition of CXCL10 at 24 h. First, we examined the levels of CXCR3 receptor expression. Consistent with previous reports [27, 28] , monocytes that were isolated from PBMCs expressed CXCR3 at low levels; however, upon stimulation with IFN-g (Fig. 3C) or LPS (data not shown), the expression of CXCR3 receptors on monocytes was significantly and uniformly elevated, which was observed similarly in human monocytic cell lines, such as THP-1 and U937 (data not shown). Blockade of the CXCR3 receptor with anti-CXCR3 Ab completely abolished the stimulatory effects of CXCL10 on IL-12 production (Fig. 3D) . We next explored whether CXCR3-mediated chemotactic signaling pathways were involved in the proinflammatory production by its ligands. Chemotactic activity Figure 2 . Analyses of the requirement of CXCL9 and CXCL11 for IFN-gprimed human monocyte production of proinflammatory cytokines. (A) CXCL9 and CXCL11 amounts produced by activated monocytes as described in Fig. 1 were assayed with AlphaLISA at indicated time points during IFN-g priming periods (blue) or LPS stimulation (red), respectively. (B) Neutralizing Abs against human CXCL9 or CXCL11 were included in cultures during IFN-g priming of monocytes (i.e., 0 h). IL-12 production was measured from the supernatants at the conclusion of 48 h of culture and was compared with that from anti-CXCL10 Ab-treated monocyte cultures. Data represent means 6 SEM of triplicates with at least 4 independent donors with similar findings. ***P , 0.001 (2-tailed, unpaired Student's t test). depends on GTPases [29] , and the MEK/ERK signaling pathways are involved in GPCR-mediated chemotaxis [30] . Treatment of IFN-g-primed monocytes with either pertussis toxin (GTPase inhibitor) or U0126 (i.e., MEK/ERK inhibitor) failed to impact CXCL10-induced IL-12 production (Fig. 3E) . Increasing amounts of these inhibitors did not have any effect on cytokine production (data not shown). We next surveyed an array of smallmolecule inhibitors for several common lymphocyte-activating signaling pathways (i.e., Tyk, Syk, Src, IKK, and p38 MAKP). Of interest, among these we found that the inhibition of either IKK or p38 MAPK, but not Tyk, Src, or Syk, pathways resulted in the complete blockade of IL-12 production (Fig. 3F and data not  shown) . Collectively, these data suggest that the IKK and p38 MAPK pathways are critical for CXCL10 to promote IL-12 production by activated monocytes.
Systemic and local CXCL10 abundance is associated with intestinal inflammatory disease CXCL10 is highly expressed during inflammatory immune responses and has been implicated in the pathogenesis of many immune-mediated diseases, such as IBD [9, 18, 31] , where it is believed to contribute to recruiting activated pathogenic T cells to inflammatory mucosal tissues; however, our findings described above suggest that CXCL10 plays an additional nonchemotactic role in the pathogenesis of inflammatory diseases (i.e., promoting the production of proinflammatory cytokines by recruited/resident myeloid-derived cells, such as monocytes, macrophages, and dendritic cells in the mucosal tissues). To explore this possibility, we first surveyed CXCL10 expression levels in patients with IBD and in an animal model of IBD. We used a CD40-induced colitis model in immune-deficient mice (i.e., SCID) to investigate the role of CXCL10 in innate-mediated intestinal damage and inflammation [22, 23] . Consistent with previous reports [9] , patients with IBD exhibited significantly higher levels of CXCL10 in sera compared with normal healthy donors (Fig. 4A) . The elevated levels of CXCL10 in patients with IBD were further corroborated by analyses of intestinal tissue biopsies (Fig. 4B) . Similarly, we also observed highly elevated CXCL10 proteins in the sera of CD40-induced colitogenic mice (Fig. 4C) . To assess whether the elevation of CXCL10 in the circulation reflects the inflammatory immune response in the gut, we examined CXCL10 proteins from colon explants ex vivo overnight and mRNA from freshly isolated tissues. Explants that were isolated from CD40-induced colitis mice induced robust CXCL10 production when measured for proteins (Fig. 4D ) and mRNA levels (Fig. 4E) . In addition to CXCL10, we also observed an elevation in an array of proinflammatory cytokines (i.e., IL-12, IL-23, TNF-a, IFN-g, IL-6) in the sera and colon explants (data not shown). Taken together, these data suggest that enhanced local production of CXCL10 and its release into the circulation are closely associated with intestinal inflammatory diseases.
CXCL10 signaling is required for innate-mediated intestinal inflammation
Anti-CD40-induced immunopathology in the intestines depends functionally on IL-12, IL-23, TNF-a, and IFN-g [22, 32] . On the basis of our earlier observation shown in Fig. 1, CXCL10 produced after CD40 ligation in SCID mice (Fig. 4B) could contribute to the activation of myeloid-derived cells at mucosal tissues in the gut to produce proinflammatory cytokines, such as IL-12 and IL-23, thus driving the progression of inflammatory Figure 3 . CXCL10 is sufficient to promote IL-12 production by human monocytes and is dependent on the CXCR3/IKK/p38 MAPK pathways. (A and B) CXCL10 is sufficient to promote IL-12 production by IFN-g-primed monocytes. Monocytes were primed with IFN-g. At 24 h, monocytes were extensively washed to remove the added IFN-g before the addition of recombinant CXCL9, CXCL10, and CXCL11. IL-12 production was measured after an additional 24 of stimulation with chemokines in the absence of LPS (A). Neutralizing Abs against CXCL9 and CXCL10 were added to IFN-g-primed monocyte cultures (i.e., 24 h). IL-12 concentration was assessed at an additional 24 h of incubation (B). Data represent means 6 SEM of triplicates with 2 independent experiments (n = 2 donors/ experiment) with similar findings. (C) CXCR3 expression on monocytes was determined by using freshly isolated human PBMCs (left) or 4 h poststimulation with human recombinant IFN-g (200 ng/ml; right). Specific staining was determined by using anti-human CXCR3 Ab (red) over isotype IgG (dark). Data are representative of 2 different donors with 3 independent experiments. (D and E) CXCL10-mediated IL-12 production was dependent on both CXCR3 engagement and IKK/p38 MAPK signaling pathways. Monocytes were primed with IFN-g overnight. Primed monocytes were washed before the addition of CXCL10. To block CXCL10 binding to CXCR3, anti-CXCR3 Ab or control Abs (IgG and anti-IL-1R) were included during CXCL10 stimulation. Anti-CXCL10 Ab was included as a positive control (D). To delineate the CXCR3 receptor-mediated chemotactic function, IFN-g-primed monocytes were pretreated with pertussis toxin (PT) or MEK inhibitor (U0126) at a 1-nM final concentration during CXCL10 stimulation (E). (F) To probe the intracellular signaling pathways for CXCL10-mediated IL-12 production, several small molecules that inhibited p38 MAPK, IKK, Tyk2, and BTK activities were included in parallel with CXCL10 stimulation. IL-12 production in the supernatants was measured after an additional 24 h of incubation with AlphaLISA. Data represent means 6 SEM of triplicates with at least 2 independent experiments (n = 2 donors/experiment). ***P , 0.001 (2-tailed, unpaired Student's t test).
responses that result in chronic inflammatory immune responses and tissue damage in mucosal tissues. To explore the role of CXCL10 in the pathogenesis of innate-mediated intestinal inflammation and tissue destruction, we interfered with CXCL10 signaling by prophylactically administering CXCL10 neutralizing Ab. SCID mice that were treated with anti-CD40 Ab received isotype control Ab or anti-CXCL10 neutralizing Ab, and the parameters of clinical disease were monitored. Compared with control Ig-treated mice, anti-CXCL10 Ab-treated mice exhibited slightly reduced weight loss (Fig. 5A) ; however, histologic examination of colon tissue revealed that anti-CXCL10 Ab dramatically improved pathologic changes within the intestinal mucosa, including smooth muscle hyperplasia (Fig. 5B) , and that this improvement by anti-CXCL10 Ab is dose dependent (Fig.  5C) . Furthermore, blockade of CXCL10 diminished neutrophil (Fig. 5D, left) and monocyte (Fig. 5D, right) infiltration into the mucosal and submucosal areas. Consistent with the histologic manifestation, CXCL10 blockade led to the simultaneous reduction of production and secretion of a variety of proinflammatory mediators, such as IL-12, TNF-a, and IL-6, in the circulation (Fig. 5E) . Lastly, TNF-a is expressed at elevated levels in IBD and is one of the central cytokines in the underlying pathogenesis of mucosal inflammation in IBD. We observed that the blockade of CXCL10 in CD40-induced innate-driven colitis resulted in significantly less TNF-a production from LPLs that were isolated from colons (Fig. 5F ) as well as TNF-a gene expression from the colon (Fig. 5G ) and protein production from the ex vivo culture of colon explants overnight (Fig. 5H) . Collectively, these data suggest that the action of CXCL10 is as a critical innate immune activator and that it may contribute to the development of inflammatory diseases in the intestines.
DISCUSSION
Myeloid-derived cells (i.e., monocytes and macrophages) are one of the most widely distributed leukocytes in tissues and are considered to be important cell types both for maintaining homeostasis and for driving local inflammation [4] [5] [6] . In the intestinal mucosa, these myeloid cells represent the most abundant cell types that are critical for both maintaining gut tolerance and driving gut inflammation. They do so, in part, by facilitating communication between the innate and adaptive immunity [5] . In inflamed intestines, mononuclear phagocytes interact with innate immune cells (e.g., ILCs and NK cells) and adaptive immune cells (i.e., T cells), which promote the local innate and adaptive immune responses, respectively. Thus, studying the mechanism by which mononuclear phagocytes are regulated in inflamed tissue will reveal the intricate interplay between the innate and adaptive immunity in the pathogenesis of intestinal diseases, such as IBD. In this report, we uncover a novel role for CXCL10 in mediating such inflammatory responses orchestrated by myeloid cells.
The results presented here provide the evidence for a nonclassic function of the chemokine, CXCL10, that regulates the activation of innate immune cells and promotes intestinal tissue injury. Our data that demonstrate that the CXCL10/ CXCR3 axis mediates monocyte activation and drives tissue inflammation by innate immunity differ from the conventional view of the CXCL10/CXCR3 axis as an immune cell trafficker [25] . Our data demonstrate a distinct role for CXCL10 that, compared with CXCL9 and CXCL11, was necessary and sufficient for IFN-g-primed monocytes to produce proinflammatory cytokines, which indicates a nonredundant role of CXCL10 in inflammation. CXCL9, CXCL10, and CXCL11 are members of the CXC chemokine family and bind and activate the same CXCR3 receptor [33] . Although these CXCR3 ligands can all be induced by IFN-g, they seem to mediate distinct biologic functions [17, 34] . Our data that suggest that CXCL10 and, to a lesser degree, CXCL9, but not CXCL11, are capable of triggering monocytes to produce IL-12 and IL-23 are in line with this notion; however, it is noteworthy that CXCL10 signaling alone, even though sufficient, may provide a weak signal for cytokine production by monocytes as CXCL10 plus LPS synergized to produce much greater amounts of IL-12 and IL-23. These findings trigger the intriguing possibility that the CXCR3 ligands exhibit a degree of functional diversity that may reflect their differential roles in regulating nonchemotactic vs. chemotactic responses. This functional diversity could be dictated at least by 2 different mechanisms. First, the distinct cellular responses among the ligands in vivo may be related to the temporally and spatially dependent differential expression of , respectively) were used to measure CXCL10. Samples from healthy volunteers (HVs) were used as control. CXCL10 from biopsies was measured from the supernatants of explant cultures overnight. *P , 0.05; **P , 0.01; ***P , 0.001 (2-tailed, unpaired Student's t test). (C-E) Colitis in SCID mice was induced by treatment with anti-CD40 Ab i.p. Anti-CD40 Ab-treated mice were examined at day 6 for CXCL10 protein in serum (C) and explant culture supernatants (D). In addition, mRNA levels of CXCL10 in colon tissues were examined at day 6 post-treatment (E). Data represent means 6 SEM of at least 2 independent experiments (C-E; n = 4-6 mice/group per experiment). *P , 0.05; **P , 0.01; ***P , 0.001 (2-tailed, unpaired Student's t test).
these ligands, as has been shown for graft rejection, atherosclerosis, infection, and inflammatory diseases. Second, the differential biologic outcomes may stem from the differential activation of CXCR3 by CXCL10, CXCL9, and CXCL11 [17, 33, 34] . This differential activation results, at least in part, from the differential receptor binding affinity and/or mode. For instance, CXCL11 exhibits significantly higher affinity to CXCR3 with a greater chemotactic response than CXCL9 and CXCL10 [17] .
The ligands' differential mode of engagement for the receptor, in turn, may be dictated by the different binding domains within the extracellular loops of the receptor, thereby activating distinct intracellular loops of the receptor [33, 34] . Thus, it is conceivable that the distinct binding of CXCL10, compared with CXCL9 and CXCL11, to CXCR3 expressed by monocytes transduces intracellular signals and activates the p38 MAPK/IKK pathways [21, 35] . The detailed evaluation of the interaction residues that are ) present in the colons of CD40-induced colitic SCID mice were examined at day 6 post-treatment from the single-cell suspension of colon LPL after 4 h of stimulation with PMA/ionomycin in the presence of Golgi Stop. (G and H) Colon explants prepared at day 6 post-treatment were directly examined for TNF-a mRNA (G; anti-CXCL10 Ab at 25 mg/kg) or incubated overnight to examine TNF-a released into the supernatants (H). Data indicate means 6 SEM (D-G and H; n = 4-6 mice/group) from a representative of 2 independent experiments. *P , 0.05; **P , 0.01; ***P , 0.001 (2-tailed, unpaired Student's t test).
involved in the formation of the CXCL10/CXCR3 complex in relation to the capacity of monocytes to produce cytokines remains to be determined.
Soluble immune mediators, such as cytokines and possibly chemokines, can act as alarmin, which is released rapidly upon cellular damage to activate local resident cell populations of tissues [36] [37] [38] . CXCL10 is present in normal intestines, likely in response to microbiota, and rapidly induced during dysbiosis or/and immune dysregulation. Our findings that demonstrate that CXCL10 is a potent in vitro and in vivo stimulus for inducing proinflammatory cytokines in myeloid-derived cells shed light on its potential role in establishing gut homeostasis and during intestinal inflammation. Intestinal epithelial cells are constantly bombarded with myriad foreign entities, including microbiota and its byproducts, and the maintenance of balance between host and the microbial activity at the interface is a quintessential process required for the integrity of intestinal mucosa. Our study may suggest that one important function of CXCL10 in gut homeostasis might be to activate (or alarm) the local innate immune system to keep the gut microbiome under control; however, during dysbiosis or abnormal immune responses, CXCL10 likely leads to the damage of intestinal barriers by virtue of its abundance and capability to activate myeloidderived cells to produce tissue-damaging cytokines (i.e., IL-12, IL-23, and TNF-a). It is also noteworthy that CXCL10 influences the differentiation of naïve CD4 T helper cells that skew toward proinflammatory Th1 cells and their recruitment to the site of inflammation [17, 18] . Of note, our study does not exclude chemotactic effects on myeloid cells. Instead, similar to its role in T cell induction and recruitment, CXCL10 may play dual roles in myeloid cells: activation and recruitment. It is an intriguing possibility that proinflammatory cytokines (i.e., IL-12/23) that are produced by myeloid cells after CXCL10 engagement could promote Th1 responses indirectly, and the resulting IFN-g that is released from Th1 cells, in turn, further induce CXCL10 via a feed-forward mechanism. In addition to its canonical role in regulating immune cell migration, these novel findings collectively support the notion that, under some circumstances, CXCL10 may serve an alarmin function to initiate proinflammatory responses and shape inflammatory adaptive immunity [18, 31] as well as contribute to the pathogenesis of inflammatory diseases, such as IBD, when it is produced in excess [39] .
Our data reveal that CXCL10 could drive intestinal inflammation by mediating monocyte production of proinflammatory cytokines in vivo in the innate model (devoid of T/B-mediated adaptive immunity) of colitis after CD40/CD40L ligation. In this model, CXCL10 could stem from innate immune cells (e.g., monocytes and dendritic cells) and stromal cells (e.g., endothelial cells and epithelial cells) via CD40 signaling [22, 23, 32] . Elevated IFN-g-the critical inducer of CXCL10 production-was observed after the initiation of colitis. The main producers of IFN-g in this model (i.e., SCID) include ILC1 and NK cells [40] . IFN-g production from these innate cells could act on innate cells, such as monocytes (and possibly stromal cells), in the intestines, which results in CXCL10 production. Autocrine and paracrine action of CXCL10, in turn, promotes the IFN-g-primed monocytes to produce colitogenic proinflammatory cytokines (i.e., IL-12, IL-23, and TNF-a) [22] . Of note, blocking CXCL10 in this innate immune colitis model also suppressed the colonic production of IFN-g. Furthermore, CXCL10 may also serve as an important mediator for the reciprocal activation of monocytes and ILC1/NK cells-critical innate cell types that are involved in gut inflammation. Taken together, our data support the view that the feedforward loop between IFN-g and CXCL10 produced by ILC1/NK cells and monocytes, respectively, prolong and amplify intestinal inflammation and contribute to tissue damage.
Chemokines play a key role in immune and inflammatory responses by promoting the recruitment and activation of different subpopulations of leukocytes, thus having important proinflammatory and immune modulatory functions [18, 25] . Identification of the novel biologic mode of action by which CXCL10 delivers a molecular cue to myeloid-derived cells for the induction of proinflammatory responses brings an opportunity for treatment of inflammatory diseases (i.e., IBD). Current treatment with anti-TNF-a agents often produces clinical improvement in patients with IBD; however, no more than one third achieves true remission, and in many cases the response is only short lived [41, 42] . Considering the life-long nature of these diseases, there is a real need for novel therapies that target components of the pathogenic response other than the TNF-a pathway. Thus, it is conceivable that anti-CXCL10 Ab, alone or in combination with anti-TNF-a Ab, might prove beneficial in patients with IBD that is refractory or who have inadequate response to anti-TNF-a treatment. AUTHORSHIP Q.Z., T.K., J.P., J.W. and W.S. performed the experiments and interpreted the data. X.Y., Y.S., H.Z., H.S., V.R., S.D., H.T., M.E.C., R.W., T.O., and J.X. contributed to specific experiments. M.S. and L.S.-C. designed, analyzed, discussed the data and edited the manuscript. Q.Z. and T.K. designed the experiments, interpreted the data, and wrote the manuscript.
